As of May 28, 2025, Enlabs AB has a Discounted Cash Flow (DCF) derived fair value of $11.90 per share. With the current market price at $53.10, this represents a potential upside of -77.6%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $8.00 |
| DCF Fair Value (10-year) | $11.90 |
| Potential Upside (5-year) | -84.9% |
| Potential Upside (10-year) | -77.6% |
| Discount Rate (WACC) | 5.4% - 7.5% |
Revenue is projected to grow from $50 million in 12-2020 to $152 million by 12-2030, representing a compound annual growth rate of approximately 11.8%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2020 | 50 | 27% |
| 12-2021 | 53 | 5% |
| 12-2022 | 64 | 21% |
| 12-2023 | 76 | 18% |
| 12-2024 | 85 | 12% |
| 12-2025 | 95 | 12% |
| 12-2026 | 107 | 12% |
| 12-2027 | 118 | 11% |
| 12-2028 | 129 | 9% |
| 12-2029 | 142 | 10% |
| 12-2030 | 152 | 7% |
Net profit margin is expected to improve from 30% in 12-2020 to 36% by 12-2030, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2020 | 15 | 30% |
| 12-2021 | 16 | 29% |
| 12-2022 | 20 | 31% |
| 12-2023 | 24 | 32% |
| 12-2024 | 28 | 33% |
| 12-2025 | 33 | 35% |
| 12-2026 | 37 | 35% |
| 12-2027 | 41 | 35% |
| 12-2028 | 46 | 35% |
| 12-2029 | 50 | 36% |
| 12-2030 | 54 | 36% |
with a 5-year average of $2 million. Projected CapEx is expected to maintain at approximately 7% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2021 | 3 |
| 12-2022 | 3 |
| 12-2023 | 4 |
| 12-2024 | 4 |
| 12-2025 | 5 |
| 12-2026 | 6 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 17 |
| Days Inventory | 0 |
| Days Payables | 42 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2021 | 12 | 1 | 4 | 0 | 8 |
| 2022 | 16 | 1 | 4 | 0 | 10 |
| 2023 | 19 | 1 | 5 | 0 | 13 |
| 2024 | 23 | 1 | 6 | 0 | 16 |
| 2025 | 27 | 1 | 6 | 0 | 19 |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 8.00 | -84.9% |
| 10-Year DCF (Growth) | 11.90 | -77.6% |
| 5-Year DCF (EBITDA) | 2.29 | -95.7% |
| 10-Year DCF (EBITDA) | 3.95 | -92.6% |
Is Enlabs AB (NLAB.ST) a buy or a sell? Enlabs AB is definitely a sell. Based on our DCF analysis, Enlabs AB (NLAB.ST) appears to be overvalued with upside potential of -77.6%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $53.10.